In the last trading session, 2.12 million shares of the Mersana Therapeutics Inc (NASDAQ:MRSN) were traded, and its beta was 1.59. Most recently the company’s share price was $0.44, and it changed around $0.01 or 4.56% from the last close, which brings the market valuation of the company to $55.44M. MRSN currently trades at a discount to its 52-week high of $4.95, offering almost -1025.0% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 9.09% since then. We note from Mersana Therapeutics Inc’s average daily trading volume that its 10-day average is 2.76 million shares, with the 3-month average coming to 5.65 million.
Mersana Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended MRSN as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Mersana Therapeutics Inc is expected to report earnings per share of -0.19 for the current quarter.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Instantly MRSN has showed a green trend with a performance of 4.56% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4729 on recent trading dayincreased the stock’s daily price by 6.96%. The company’s shares are currently down -68.90% year-to-date, but still down -7.14% over the last five days. On the other hand, Mersana Therapeutics Inc (NASDAQ:MRSN) is -16.58% down in the 30-day period. We can see from the shorts that 10.32 million shares have been sold at a short interest cover period of 2.26 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 85.33% from its current value. Analyst projections state that MRSN is forecast to be at a low of $3 and a high of $3.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
The year-over-year growth rate is expected to be -31.79%, down from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 6.05M in revenue for the current quarter. 8 analysts expect Mersana Therapeutics Inc to make 6.12M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 9.24M and 2.29M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -34.58%. Forecasts for the next quarter put sales growth at 166.98%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 2.74%. Mersana Therapeutics Inc earnings are expected to increase by -29.24% in 2025, but the outlook is negative -13.09% per year for the next five years.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.40% of Mersana Therapeutics Inc shares, and 85.52% of them are in the hands of institutional investors. The stock currently has a share float of 86.73%. Mersana Therapeutics Inc stock is held by 169.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 15.8156% of the shares, which is about 19.36 million shares worth $38.92 million.
VR ADVISER, LLC, with 9.2519% or 11.33 million shares worth $22.77 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.47 shares worth $1.54 million, making up 2.78% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 3.11 shares worth around $1.38 million, which represents about 2.50% of the total shares outstanding.
